A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)
An Open-Label, Systemic Gene Delivery Study to Evaluate the Safety, Tolerability and Expression of SRP-9001 in Association With Imlifidase in Subjects With Duchenne Muscular Dystrophy With Pre-existing Antibodies to rAAVrh74
Sponsor: Hansa Biopharma AB
Terminated
Study is being terminated due to a business decision.
Other terminated trials from Hansa Biopharma AB
- Anti-Glomerular Basement Membrane Antibody Disease · Phase PHASE3 · Feb 2026
- Kidney Transplantation in Highly Sensitized Patients · Phase PHASE2 · May 2024
- Kidney Transplant Rejection · Mar 2023
- Purpura, Thrombotic Thrombocytopenic · Phase PHASE2 · Jan 2017
More terminations from Hansa Biopharma AB
Other Duchenne Muscular Dystrophy trials with similar outcome
This PHASE1 trial investigates Duchenne Muscular Dystrophy and is currently terminated or withdrawn. Hansa Biopharma AB leads this study, which shows 6 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE1
Status: Enrolling By Invitation → Terminated
-
Apr 2025 — Dec 2025 [monthly]
Enrolling By Invitation PHASE1
-
Sep 2024 — Apr 2025 [monthly]
Enrolling By Invitation PHASE1
Status: Active Not Recruiting → Enrolling By Invitation
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Enrolling By Invitation → Active Not Recruiting
▶ Show 1 earlier version
-
Mar 2024 — Apr 2024 [monthly]
Enrolling By Invitation PHASE1
First recorded
Jan 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hansa Biopharma AB
- Sarepta Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .